suppressed and patients reported felling well. Urine analysis failed to detect any presence of opiate metabolites. No withdrawal symptomatology recurred after 8 days of treatment when GHB was suspended, and patients were challenged with an intravenous injection of 0.4 mg naloxone. The results indicate that GHB may be useful in the management of opiate withdrawal. [Neuropsychopharmacology 9:77-81, 1993] sidered to function either as a neurotransmitter or neuromodulator rather than as an incidental metabo lite of gamma-aminobutyric acid (GABA) (Mandel et al. 1987) .
Gamma-hydroxybutyric acid has been used as an intravenous hypnotic and anesthetic agent (Mamelak et al. 1977) and in the treatment of narcolepsy. In the latter condition, GHB is given orally at bedtime to im prove nocturnal sleep quality, thus reducing cataplexy episodes during the day (Mamelak et al. 1986 ). Previ ous work in animals has shown that GHB both inhibits voluntary ethanol consumption in rats having a strong preference for ethanol and suppresses the ethanol withdrawal syndrome in rats physically dependent on ethanol (Fadda et al. 1989a (Fadda et al. , 1989b .
More recently, in a double-blind study we found that GHB, given orally in nonhypnotic doses, is highly effective in suppressing the withdrawal symptomatol ogy in alcoholics; the GHB effect being rapid and de void of negative side effects (Gallimberti et al. 1989) . By using GHB in the management of the withdrawal syndrome in a number of alcoholics who concomi tantly abused heroin, we observed that GHB not only suppressed the alcohol withdrawal symptomatology 0893-133X/93/$6.00 but, even more effectively, that of heroin. The present study was undertaken to clarify, in a double-blind con dition, whether GHB was effective in suppressing the withdrawal syndrome in heroin-and methadone-de pendent subjects.
SUBJECTS AND METHODS
The subjects participating the study were 22 male heroin users, with a mean age of 27.3 years (range 22 to 33 years), with a clear history of daily use of heroin for over 3 years (3 to 6 years) claiming a high degree of opiate dependence; and 19 male subjects, with an age ranging from 24 to 31 years (mean 28 years) under going a methadone maintenance treatment program at the Addiction Treatment Service (SERT, USL 21), Cagliari.
Methadone-maintained subjects were receiving a stabilized dose of 30 to 60 mg/day of methadone for at least 6 months prior to hospitalization. All subjects were interested in discontinuing opiate consumption and gave informed consent to the study. The present study required hospitalization for a period of 8 days. Subjects were hospitalized on the morning of the day following their last consumption of opiates. On admis sion each subject underwent a medical and psychiatric examination, routine laboratory tests, urine screening analysis for opiate metabolites, amphetamine, co caine, benzodiazepines, barbiturates, cannabinoids, and alcohol.
The fIrst test revealed that all heroin-dependent subjects had urinary opiate metabolites. All subjects under methadone maintenance presented methadone metabolites, three of whom revealed also other opiate metabolites. Small concentrations of alcohol and ben zodiazepine metabolites were found in the urine of both groups of patients. After admission, methadone maintained subjects were left with no opiate adminis tration for 24 hours and the rating of withdrawal symp tomatology was started at 8 AM on the second day of hospitalization. Fifteen of the 22 heroin-dependent subjects showed overt signs of abstinence on the morn ing of the day of admission; therefore, the rating of withdrawal symptomatology for these subjects was made on the morning of the same day of admission. The other seven heroin-dependent subjects, who showed objective signs of abstinence after 6 PM on the day of admission, received 1 or 2 intramuscular doses of 15 mg of morphine to ease their discomfort (no morphine was given after midnight) and their withdrawal symp tomatology was scored on the second day of hospital ization starting at 8 AM as for methadone-maintained subjects.
Withdrawal symptomatology was evaluated by one of the investigators (either RP or PPP) blind to the NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.1 treatment conditions. Twenty-one items associated with the withdrawal syndrome were rated as present
(1) or absent (0), according to Gold et al. (1978) ; the maximum score attainable was 21. Symptoms consid· ered included: craving, nausea, anorexia, anxiety and restlessness, aching bones and muscles, insomnia or yen sleep, and hot and cold flashes. Signs considered comprised: tremors, yawning, vomiting, diarrhea, perspiration, lacrimination, rhinorrhea, increased res· piration rate and depth, goose flesh, mydriasis, spon· taneous orgasm, increased temperature, tachycardia, and increased blood pressure.
Withdrawal scoring was made every 30 min utes for 3 hours prior to treatment (baseline period) and at various times afterwards, as indicated in the Results Section. The experiment was randomized and double blind; subjects, nurse, and physician observer were unaware of the substance administered. Active medi· cation, consisting of GHB 17% solution in a black cherry syrup, and an identical placebo were provided by CT (San Remo, Italy). Subjects took GHB orally at the dose of 25 mg/kg or the placebo syrup. Treatments were given by a nurse who was not otherwise in· volved in the study. The Mann-Whitney U-test was used to test differences between placebo and GHB treatment. A modifled Wilcoxon test (Pratt's test) was applied for within-patient comparison.
RESULTS
All methadone-and heroin-dependent subjects showed signs and symptoms of abstinence that increased duro ing the 3 hours preceding treatment. Table 1 shows the reported withdrawal scores obtained during the 30 minutes preceding treatment and at various times af· ter treatment. The administration of GHB (25 mg/kg) reduced most of the withdrawal signs and symptoms both in heroin-and methadone-dependent subjects. The GHB effect had a rapid onset but short duration. Thus, the global withdrawal score was signilicantlyre duced within 15 minutes and remained maximall y suppressed between 30 minutes and 2 hours after treatment. At the third hour, withdrawal scores tended to increase once again. Table 2 shows the effect of GHB on specifIc items of the opiate withdrawal scale. It appears that GHB was effective in reducing aD the signs and symptoms of opiate withdrawal, exce� for diarrhea and insomnia, which were resistant to the GHB effect. All patients on GHB referred to relief 01 subjective distress. Placebo had no signiflcant effect on any of the withdrawal items; therefore, at the end of the double-blind trial, these patients were assigned to a more conventional detoxifIcation treatment with clonidine or methadone.
On the other hand, patients on GHB continued o M .... 
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this treatment receiving the drug in an open study ev ery 2 to 4 hours on the frrst 2 days and every 4 to 6 hours the following 6 days, as indicated by the phar macokinetics of GHB (Lettieri and Fung 1979, Ferrara et al. 1992) . Every day, withdrawal signs and symp toms were recorded before each dose. The withdrawal score remained reduced throughout the trial. On the eighth day, GHB administration was suspended, sub jects were observed during a period of 5 to 6 hours, and then received an intravenous injection of 0.4 mg of naloxone. No withdrawal signs and symptoms oc curred before and after naloxone treatment (see Table   I ). Urine analysis performed every other day during the trial failed to detect the presence of opiate metabo lites. Three methadone-dependent and two heroin dependent subjects reported transient dizziness or vertigo on the second and/or third day following the fIrst morning dose of GHB; these symptoms were usu ally well tolerated. No other side effects attributable to this compound were noted either by the observer or the subjects themselves. None of the subjects reported somnolence after GHB.
DISCUSSION
The standard method used in the management of heroin withdrawal is the substitution of methadone for heroin and gradual dose reduction until complete abstinence is obtained. More recently the alpha-2 agonist, clonidine, has been introduced to facilitate withdrawal from opioids. Although clonidine is effec tive in reducing many of the autonomic components of the withdrawal syndrome, it fails to suppress its subjective components, such as craving, lethargy, in somnia, and restlessness. Moreover, it is not uncom mon for clonidine to produce major side effects, such as sedation and severe hypotension (see Jaffe 1987). Consequently, fInding a nonopioid drug capable of suppressing withdrawal symptomatology without causing negative side effects is of prime importance.
Our results indicate that GHB is effective in suppress ing the opiate withdrawal syndrome in humans. The GHB effect has a rapid onset but short duration. These features are in accordance with the pharmacokinetics of GHB, indicating that the compound is readily ab sorbed after oral administration and is rapidly elimi nated (Lettieri and Fung 1979; Ferrara et al. 1992 ). Due to the short duration of its effect, GHB should be ad ministered at frequent intervals. This is a limitation of an otherwise effective and well-tolerated compound. The mechanism by which GHB suppresses opiate withdrawal syndrome is not known. A number of mechanisms may be invoked but none can be convinc ingly accepted. It is possible to discount the sedative effect of the compound because no sedation was pro- Data for heroin-(n = 14) and methadone-(n = 13) dependent subjects were pooled. The 21 items of the scale were rated as present (1) or absent (0) according to Gold et al. (1978) .
duced by those doses of GHB suppressing opiate with drawal. Experimental evidence indicates that GHB in terferes with the activity of serotonin (Spano and Przegalinski 1973) , acetylcholine (Sethy et al. 1976) , GABA (Snead and Nichols 1987) , and dopamine (DA) (Gessa et al. 1968) in the CNS. The interference of GHB with DAergic transmission might be more rele vant for its suppressant effect on the withdrawal syn drome. Indeed, recent studies have shown that both ethanol and morphine withdrawal syndromes are as sociated with profound inhibition of DA output in the nucleus accumbens and in the ventral caudate nu cleus, as measured by brain micro dialysis (Rossetti et al. 1990 (Rossetti et al. , 1991 Acquas et al. 1991) .
Contrary to what was observed following anes thetic doses of GHB (Walters et al. 1973) , we have re cently found that nonanesthetic doses of the com pound activate the fIring rate of DAergic neurons (Diana et al. 1991), and Cheramy et al. (1977) have reported that GHB increases DA release from the cau date nucleus of cats. Because the increase in DA out put is considered to play an important role in the re warding effects of morphine and alcohol (Di Chiara and Imperato 1988) , it is reasonable to hypothesize that the fall in DA output might be involved in the negative symptoms of withdrawal and, vice versa, a stimulation of DA output might be implicated in the suppressant effect of GHB on withdrawal symptoma tology.
Alternatively, it should also be considered that GHB is a normal brain constituent, which seems to function as a neurotransmitter or neuromodulator (Mandel et al. 1987) . Therefore possible changes in the endoge nous content and activity of this compound in the pathogenesis of withdrawal from opiates and al cohol are worth specifIc investigation. Whatever the mecha· nism of action of GHB, its efficacy in suppressing both opiate and alcohol withdrawal syndrome is of practical importance, because a combination of opiate and alco hol abuse is not uncommon. Results in preparation from our group have shown that GHB prevents the emergence of opiate withdrawal signs and symptoms evoked by naloxone in opiate-dependent patients.
